Freeline Therapeutics down on wider loss, names new CEO
16/08/2021 13:43
** Shares of the gene therapy co FRLN.O down as much as
2.11% at $3.25 premarket
** Freeline Therapeutics names Michael Parini as new CEO,
replacing Theresa Heggie
** Parini has served as the co's president and chief
operating officer
** Co also posts wider loss in Q2, hurt by higher research
and development expenses urn:newsml:reuters.com:*:nGNX6wBtVt
** Stock down ~81% YTD, as of last close
(Reporting by Rithika Krishna in Bengaluru)
((Rithika.Krishna@thomsonreuters.com;))